Prostate Cancer

CHICAGO – In this Healio video exclusive, Edwin M. Posadas, MD, FACP, discusses the redifferentiation of prostate cancer by using a humanized monoclonal antibody that inhibits CD105-mediated signaling.

Several practice-changing clinical trials in recent years have led to the understanding that combination treatments are most effective for patients with advanced prostate cancer.

In these videos, Tanya Dorff, MD, professor in the  Department of Medical Oncology & Therapeutics Research and serves as section chief of the Genitourinary Disease Program at City of Hope discusses the role of hormone blocking therapies in prostate cancer care.

In these videos, Tanya Dorff, MD, professor in the  Department of Medical Oncology & Therapeutics Research and serves as section chief of the Genitourinary Disease Program at City of Hope discusses the role of hormone blocking therapies in prostate cancer care.

In these videos, Tanya Dorff, MD, professor in the  Department of Medical Oncology & Therapeutics Research and serves as section chief of the Genitourinary Disease Program at City of Hope discusses disparities in care that exist in the treatment of prostate cancer.

In these videos, Tanya Dorff, MD, professor in the  Department of Medical Oncology & Therapeutics Research and serves as section chief of the Genitourinary Disease Program at City of Hope discusses risk factors for prostate cancer.

In these videos, Tanya Dorff, MD, professor in the  Department of Medical Oncology & Therapeutics Research and serves as section chief of the Genitourinary Disease Program at City of Hope discusses the latest developments in prostate cancer treatment.

FDA approved talazoparib plus enzalutamide for treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

FDA announced the creation of a voluntary pilot program that will assist clinicians in selecting the appropriate treatment for patients with cancer through the use of laboratory-developed tests, according to an FDA press release.

CHICAGO Adding prostate irradiation to standard systemic therapy extended radiographic PFS among men with newly diagnosed low-volume metastatic castration-sensitive prostate cancer, according to results of the PEACE-1 trial.